Prof. John Marshall (Ruesch Center for the Cure of Gastrointestinal Cancer, and, Georgetown University Hospital, Washington, DC, USA) joins us to discuss the major highlights in upper gastrointestinal cancers. Prof. Marshall highlights the K-UMBRELLA study, a biomarker-integrated trial for second-line treatment of advanced gastric cancer (0:33); randomized phase 2 trial of the AIO (2:46); and finally he discusses the phase Ib/II study of CLDN18.2 CAR T-cell therapy, investigating safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma (3:50).
ASCO 2022 Abstracts discussed in this interview:
- Abstract #4001: The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC)
- Abstract #4043: FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase 2 trial of the AIO
- Abstract #4017: Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041)
Disclosures: John Marshall is consultant for, and has received honoraria/honorarium from Bayer, Caris, Indivumed, Merck and Pfizer. He is a Speaker’s Bureau participant with Bayer, Caris, Merck and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
